Bridgewater Associates LP Takes $674,000 Position in BioNTech SE (NASDAQ:BNTX)

Bridgewater Associates LP bought a new position in BioNTech SE (NASDAQ:BNTX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,673 shares of the company’s stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also bought and sold shares of BNTX. FMR LLC boosted its position in BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after buying an additional 5,598,190 shares during the period. Candriam S.C.A. boosted its holdings in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares during the period. Point72 Asset Management L.P. grew its position in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the last quarter. New York State Common Retirement Fund increased its stake in BioNTech by 457.9% in the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares during the period. Finally, abrdn plc lifted its position in BioNTech by 334.4% in the third quarter. abrdn plc now owns 225,992 shares of the company’s stock valued at $26,841,000 after purchasing an additional 173,969 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BioNTech stock opened at $117.20 on Tuesday. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The firm has a market capitalization of $28.10 billion, a P/E ratio of -56.68 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $113.81 and a two-hundred day simple moving average of $98.77.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lifted their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Canaccord Genuity Group boosted their price objective on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Berenberg Bank initiated coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Finally, UBS Group increased their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.